Ratings EDAP TMS S.A.

Equities

EDAP

US2683111072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.28 ^USD	-1.62%		+0.28%	+37.88%

Apr. 26	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
Apr. 25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Sales forecast by analysts have been recently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
EDAP TMS S.A.	+37.88%	270M	-
THERMO FISHER SCIENTIFIC	+8.07%	219B	B
DANAHER CORPORATION	+6.59%	183B	B-
INTUITIVE SURGICAL, INC.	+11.26%	133B	B-
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B	A-
SIEMENS HEALTHINEERS AG	+0.65%	63.06B	A-
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B	B+
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B	A
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes